MARKET NEWS

Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)
INmune Bio Announces Initiation of Clinical Program to Determine if Company’s Platform May Prevent Complications of Cytokine Storm Caused by COVID-19
Vaxart Announces Positive Preclinical Data for its Oral COVID-19 Vaccine Program
Ascendia Joins the Fight Against COVID-19; Developing Formulations
Arcutis Announces Enrollment of First Patient in Phase 1/2b Study 
COVID-19: Gattefossé Takes Measures & Continues to be Operational

  FEATURED EDITORIAL

  COMPANY PROFILE

BioDuro, an Advent International portfolio company, is a leading global life sciences research and development organization that provides biopharmaceutical clients and partners with comprehensive, fully integrated drug discovery and development services, from lead development and IND-enabling studies to GMP manufacture of drug product for clinical trials.  Core expertise includes small and large molecule discovery, development and scale-up, combined with unique technology platforms such as bioavailability enhancement of insoluble compounds. Click here for more.

  EXCLUSIVE ONLINE CONTENT


Histogen Announces Investigational Device Exemption Application

Histogen Announces Investigational Device Exemption Application

Histogen Inc. recently announced it has submitted an Investigational Device Exemption (IDE) application with the US FDA for the initiation of a….

Mogrify & Sangamo Announce Collaboration & Exclusive License Agreement 

Mogrify & Sangamo Announce Collaboration & Exclusive License Agreement 

Mogrify Ltd and Sangamo Therapeutics recently announced they have executed a collaboration and exclusive license agreement for Sangamo to develop….

Mustang Bio Receives Advanced Therapy Medicinal Product Classification

Mustang Bio Receives Advanced Therapy Medicinal Product Classification

Mustang Bio, Inc. recently announced that the European Medicines Agency (EMA) has granted Advanced Therapy Medicinal Product (ATMP) classification to….

Esperion Announces Development & Commercialization Agreement With Otsuka Pharmaceutical

Esperion Announces Development & Commercialization Agreement With Otsuka Pharmaceutical

Esperion recently announced it has entered into a collaboration agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of….

Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics    

Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics    

Q BioMed Inc. recently announced that together with its technology partner, Mannin Research, they are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 6 – Prefilled Syringes
May 13 – Particle Design Technology